|
 Home
|
|
Back
|
ADT more often delayed or withheld in black men with metastatic prostate cancer
|
MedWire News: A substantial proportion of men with metastatic prostate cancer, particularly Black men, do not receive androgen deprivation therapy (ADT) or receive delayed therapy, although such treatment does not play a role in racial survival differences, say US scientists.
ADT is known to inhibit the growth of prostate cancers in men with advanced disease, who have poor survival. However, the ideal timing for starting ADT in men with metastatic disease is unknown.
To investigate further, Nancy Keating, from Harvard Medical School in Boston, Massachusetts, and colleagues studied 8671 men aged at least 66 years, from the Surveillance, Epidemiology, and End Results database who were diagnosed with metastatic prostate cancer during 1992-2002 and followed-up to 2003.
Early ADT was defined as receiving the treatment within 4 months of diagnosis, while delayed ADT was defined as being receiving the treatment after this time. Early, delayed, and no ADT were then assessed for factors associated with treatment and the effect of treatment on survival.
Early ADT was received by 69.5% of men, while 7.3% had delayed ADT and the remainder no ADT before death. Race was most strongly related to the timing of ADT, with Black men less likely than White men to receive early ADT and more likely to receive delayed or no ADT, at 58.3% versus 71.0%, 12.7% versus 6.2%, and 29.0% versus 22.4%, respectively.
Worse survival was seen in older men, unmarried men, and men with higher comorbidity scores. Race was not associated with survival. Receipt of ADT was associated with improved survival, at a hazard ratio of 0.69, although the timing of treatment was found to have no impact on survival.
The team writes in the BJU International: "Receipt of ADT was associated with prolonged survival, but racial differences in the use of ADT did not contribute to racial differences in survival, which were not evident after controlling for patient and tumor characteristics."
BJU Int 2008; 101: 1077-1083
http://www.blackwell-synergy.com/doi/abs/10.1111/j.1464-410X.2007.07405.x
|
|
|
Search
Information for
This is an AstraZeneca International website for healthcare professionals. The site is not intended for the following audiences who should use the links below:
Zoladex news feed
Please note
Not all indications / uses of ZOLADEX are registered in all countries. Please consult local prescribing information.
Quick links
Features
Site services
|
|
| |
|
|
